Research Article - Asian Journal of Biomedical and Pharmaceutical Sciences (2021) Volume 11, Issue 83
Azurin and its protein subunit P28 as an alternative approach to anticancer therapeutics.
In 2018 the second leading basis for death is cancer with 9.6 million deaths. Some conventional therapies are chemotherapy, surgery and radiotherapy for cancer. Formation of resistance against multidrug lack of toxicity against tumor cells are limitations and adverse side effects of these therapies. A redox protein is Azurin having 128 amino acids with a size of 14 kDa and secreted by Pseudomonas aeruginosa as a periplasmic protein. A peptide from Azurin has been found having target specificity, delivery and cytotoxity like Azurin but having lesser side effects as compared to Azurin. This amphipathic peptide is formed by residues from 50-77 AA of Azurin having 209 KDa size showing very surprising results named as P28. The anticancer activity of P28 is related with its amino acids residues from 11-18 which binds to P53. The clinical trials against adult and pediatric patients have been carried out, results showed that P28 is safe with no side effect and can be used as an alternative anti-cancer therapeutic protein. In this review paper an updated detail of Azurin and P28 about mechanism of action and therapeutic strategies is described.Author(s): Faheem uz zaman, Rabia Arooj, Mubeen Fatima, Asma Basharat, Aleena Sumrin